Skip to main content

Elezanumab (ABT-555)

Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and acute ischemic stroke.

Type of Molecule

Biologic

Target

RGMa

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Spinal Cord Injury n/a
Phase 2
Acute Ischemic Stroke n/a
Phase 2